Exelixis Inc
EXELExelixis Inc (EXEL) is a biotechnology company focused on developing and commercializing innovative therapies for cancer. Founded in 1994, the company has developed a portfolio of targeted treatments, including cabozantinib, which is used for the treatment of multiple types of cancer such as kidney, liver, and thyroid cancers. Exelixis emphasizes research in oncology and aims to advance therapies that improve patient outcomes.
Company News
The article highlights two biotechnology companies, Therapeutics and Exelixis, as promising investment opportunities for 2026 due to their innovative drug pipelines and potential for significant market growth.
Adagene initiated a Phase 2 clinical trial for muzastotug (ADG126) in combination with KEYTRUDA for microsatellite stable colorectal cancer, randomizing patients to 10 or 20 mg/kg doses with anticipated trial completion in early 2027.
Merck and Eisai reported positive Phase 3 trial results for their cancer therapy combination Welireg and Lenvima in treating advanced renal cell carcinoma, demonstrating significant improvement in progression-free survival compared to rival treatments.
